Inside Precision Medicine November 2, 2022
Chris Anderson

Myriad Genetics announced on Tuesday that it acquired consumer-focused prenatal and pediatric genomic test developer Gateway Genomics for $67.5 million in cash. The deal could pay Gateway an additional an additional $32.5 million of cash payments in 2023 and 2024 if certain revenue, volume synergy and EBITDA targets are achieved.

Via the Gateway acquisition, Myriad adds the SneakPeek Early Gender DNA test to its portfolio of women’s health products. According to the companies, SneakPeek is the top selling at-home gender test for expectant families and can deliver results with 99% accuracy only six weeks into the term of a pregnancy. Other products in Myriad’s women’s health line include the Prequel non-invasive prenatal screen, Foresight carrier screen, and MyRisk Hereditary Cancer...

Today's Sponsors

Institute for Healthcare Improvement
TripleTree

Today's Sponsor

Zelis

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma / Biotech, Trends
Insulin As Preventive Care: Why Not Eliminate Patient Cost Sharing?
The most influential healthcare CEOs
New Life In Drug Importation
5 Keys For Pharma To Close The Gap On Net Zero Goals
'People's lives are at stake': Drug shortages reach a 5-year high

Share This Article